January 12, 2017
Ablynx starts Phase IIb RESPIRE study of RSV infections treatment
Ablynx has dosed the first patient in the Phase IIb “RESPIRE” dose-ranging efficacy study of ALX-0171, its novel inhaled drug…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: RSV infections